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This article is based on presentations
at the Metropolitan Diabetes Society on
11 December 2007 in New York, New
York, and at the American Diabetes Asso-
ciation’s 55th Annual Advanced Post-
graduateCourse,held1–3February2008
in San Francisco, California (these lec-
tures are available online at http://
professional.diabetes.org), summarizing
a number of somewhat divergent views
recently expressed by different speakers
on aspects type 2 diabetes treatment.
Mechanistically based treatment
considerations
At the American Diabetes Association
(ADA) Postgraduate Course, Ralph De-
Fronzo (San Antonio, TX) reviewed the
mechanisms of action and utility of vari-
ous antidiabetic drugs, suggesting that
sulfonylureas“areveryunlikelytocreatea
durable decline in A1C,” based on under-
standing of the physiology. Studies with
glimepiride (1) and glipizide (2) show
falls in fasting glucose of 40–50 mg/dl
and in A1C by 1.5%—with monotherapy
controlling 25–30% of patients—which
he characterized as “a very good effect,
initially.” However, DeFronzo said that
“after the ﬁrst 6–12 months the A1C
starts to rise progressively.” Sulfonylurea-
induced insulin secretion increases portal
insulin levels, suppressing hepatic glu-
coseproductionandloweringfastingglu-
cose to a greater extent than postprandial
glucose. In the UK Prospective Diabetes
Study (UKPDS), sulfonylureas and insu-
lin reduced microvascular risk by 37%,
but myocardial infarction, stroke, and
congestive health failure decreased by 14,
12, and 16% (none of the latter decreases
reaching statistical signiﬁcance) (3), lead-
ing DeFronzo to contend that “there is no
evidence that treatment with insulin-
based therapy” reduces macrovascular
disease.
Insulin resistance is basic to type 2
diabetes,and-cellfailurebeginspriorto
actual development of diabetes with im-
balance between insulin resistance and
insulin secretion. DeFronzo asserted that
-cell function decreases by approxi-
mately 20% by the time glucose intoler-
ance is present, so appropriate treatment
approaches must both reverse insulin re-
sistanceandimprove-cellfunction.The
ideal antidiabetic agent would correct hy-
perglycemia, prevent microvascular com-
plications, improve known cardiovascular
disease risk factors, prevent macrovascu-
lar complications, and correct the patho-
physiological disturbances responsible
for type 2 diabetes.
At the level of the liver, metformin
and thiazolidinediones (TZDs) are simi-
larlyeffectiveinimprovinginsulinaction,
althoughTZDsareconsiderablymorepo-
tent in their peripheral action. DeFronzo
stated that TZDs “unequivocally” are
-cellprotective,citingtheﬁndingsofthe
Diabetes Prevention Program (4) and
TRoglitazone In the Prevention Of Diabe-
tes (TRIPOD) (5) studies with troglita-
zone,theDiabetesREductionAssessment
with ramipril and rosiglitazone Medica-
tion(DREAM)studyﬁndingswithrosigli-
tazone (6), and the Pioglitazone In the
Prevention Of Diabetes (PIPOD) (7) and
the Actos Now for Prevention of Diabetes
(ACT NOW) studies (clinicaltrials.gov,
reg. no. NCT00220961) with prioglita-
zone. During the ﬁrst 6 months of the A
Diabetes Outcome Progression Trial
(ADOPT) of individuals with newly diag-
nosed diabetes comparing glyburide,
metformin, and rosiglitazone, glyburide
led to particular improvement, but over
time “the best drug in this study was ros-
iglitazone” (8). DeFronzo commented
that in addition to the liver, muscle, and
the -cell, “the fourth bad actor is the fat
cell,” which is also insulin resistant, lead-
ing to overproduction of fatty acids,
whichfurtherworseninsulinresistancein
liver and in muscle and impair -cell
function.
DeFronzo characterized TZDs as the
onlyagentseffectiveininhibitinglipolysis
andreducinglevelsofinﬂammatorycyto-
kines. He noted their potential beneﬁts in
nonalcoholic steatohepatitis (9). TZDs
lowerfastingglucoseby40–50mg/dl,re-
duce A1C by 1.5%, and control diabe-
tesin25–30%ofpatientsinclinicaltrials.
In studies of both drug-naive and sulfo-
nylurea-treated diabetic patients receiv-
ing placebo or one of the TZDs, A1C
decreased from 8.5 to 7%, leptin de-
creased, and adiponectin increased. Al-
though the TZDs are associated with
weight gain, given the improved meta-
bolic outcome, DeFronzo described this
as a merely “cosmetic” consequence. The
ratio of change in insulin divided by
change in glucose (a measure of insulin
secretion) and measures of insulin resis-
tancebothimprovedwithTZDtreatment,
which DeFronzo considered “deﬁnitive”
evidence of improvement in -cell func-
tion. Both pioglitazone (10) and rosiglita-
zone (11) improve nonoxidative glucose
disposal, and these drugs reduce multiple
components of the insulin receptor sub-
strate. Although rosiglitazone tends to
raise LDL and apolipoprotein (apo)B lev-
els while pioglitazone is LDL neutral and
decreases apoB and triglycerides, other
thanthelipid-loweringeffectthereislittle
difference. In the PROspective pioglitA-
zone Clinical Trial In macroVascular
Events (PROactive) study of 5,238 high-
risk type 2 diabetic individuals, pioglita-
zone nonsigniﬁcantly decreased total
events by 10% (12). DeFronzo opined
that leg revascularization was an unfortu-
nate component (“a major mistake”)
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point, as it occurred more often with pio-
glitazone. The “principal secondary end
point” of death, myocardial infarction, or
stroke did show signiﬁcant decrease. He
suggested, then, that the TZDs “have a
particular beneﬁt” (13) and that “if fat
stays in fat cells it cannot hurt you,” while
elevated levels in intramuscular, intrahe-
patic, visceral, arterial, and -cell deposi-
tion of fat all have adverse consequences.
TZDs increase fat oxidation, perhaps a
major explanation of this therapeutic
effect.
Metformin appears to act, at least in
part, by activating AMP kinase in a fash-
ion similar to its activation by exercise.
The agent decreases hepatic acetyl CoA
carboxylase and sterol response element–
binding protein 1c expression, both ef-
fects reducing hepatic gluconeogenesis.
Metformin also exhibits a weak stimula-
tory effect on muscle glucose uptake,
possibly involving AMP kinase and po-
tentially further contributing to the glyce-
mic effect of metformin. In the UKPDS,
there was a 29% reduction in microvas-
cular disease, and there were 39, 41, and
42% decreases in myocardial infarction,
stroke, and death, respectively, leading
DeFronzo to suggest that metformin is
preferable to sulfonylureas as initial ther-
apy. He did not discuss the troublesome
increaseindiabetes-relatedmortalityseen
in the UKPDS with the combination of
sulfonylureas plus metformin vs. sulfo-
nylureas alone (14). The progressive rise
in A1C in the UKPDS also occurred with
metformin, leading DeFronzo to con-
clude that the drug does not stabilize
-cell function.
Exenatide and liraglutide are incretin
analogs, representing the use of “a very,
very old concept,” described nearly 80
years ago by La Barre (15), that oral glu-
coseelicitsagreaterinsulinresponsethan
intravenous glucose in response to an
equivalent hyperglycemic stimulus. The
effect is mediated by glucagon-like pep-
tide (GLP)-1 and glucose-dependent in-
sulinotropic polypeptide, produced by
the L-cells of the ileum and the K-cells of
the duodenum, respectively, in response
to neuronal signals to the presence of car-
bohydrate in the gastrointestinal tract,
withGLP-1alsohavingeffectsonappetite
and gastric emptying. Both GLP-1
and glucose-dependent insulinotropic
polypeptide are rapidly degraded by
dipeptidyl peptidase (DPP)-4, so GLP-1–
based therapy can involve either prolon-
gation of half-life by DPP-4 inhibition or
administration of a GLP-1 receptor ago-
nist. DeFronzo suggested that GLP-1 re-
ceptor analogs also may preserve -cell
function, though he expressed reserva-
tionsaboutwhetherDPP-4inhibitorswill
bedemonstratedtoproducethiseffect.In
initialstudies,exenatideincreasedinsulin
secretion in type 2 diabetic patients in a
dose-related and glucose-sensitive fash-
ion (16). Metformin-treated type 2 dia-
betic patients receiving 5 and 10 g
exenatide twice daily showed a reduction
in A1C by 1.0 and 1.2%, respectively,
from baseline levels of 8.3%, with evi-
dence of persistence of the effect over 3.5
years in an open-label extension study
(although one must realize that this fails
toreachthelevelofevidenceofarandom-
ized controlled trial such as ADOPT and
the UKPDS). Even in the absence of
weightloss,a0.7–0.8%reductioninA1C
was seen, while patients also exhibiting
weight loss showed a 1.7% decrease in
A1C at 82 weeks in the open-label study.
Liraglutide, DeFronzo said, “works in
a different way,” primarily lowering fast-
ing glucose, with improvement in A1C
similar to that seen with exenatide. Anal-
ysis of response to the DPP-4 inhibitor
sitagliptin showed 0.6, 0.7, and 0.9% re-
ductions in A1C in monotherapy and in
combination with metformin and piogli-
tazone, respectively, with better effect in
newly diagnosed patients (17–20). Sita-
gliptin does not delay gastric emptying or
increase splanchnic glucose uptake and is
weight neutral. A meta-analysis of studies
of GLP-1 receptor agonists and of the
DPP-4 inhibitors reported a 0.2% greater
A1C response with the former, which
were also associated with weight loss,
leading DeFronzo to suggest that these
NEWS FROM THE FOOD AND DRUG ADMINISTRATION
From time to time, new announcements by the FDA pertaining to aspects of diabetes
treatment will be highlighted in this section.
A number of agents used or having potential to be used in diabetes treatment
have come under scrutiny by the FDA for potential adverse effects related to
malignancy.AconcernaboutRegranex(becaplermin)gel,usedforthetreatment
of lower-extremity ulcers, was recently updated with a boxed warning addition
to the prescribing information for the agent, based on a study suggesting in-
creased risk of death from cancer in patients treated with three or more tubes of
Regranex compared with those who did not use the product. The FDA makes a
particular point of recommending that the potential risks of using this agent be
discussed with patients and only be used when beneﬁts can be expected to
outweigh the risks. This recommendation is in certain ways similar to the boxed
warning made for erythropoiesis-stimulating agents several months ago, al-
though there the caution was that people with existing malignancy may have
increasedmortalityandmorerapidtumorprogression.Therehasbeeninterestin
the role of tumor necrosis factor (TNF)- in mediating aspects of insulin resis-
tance,withanimalmodelsofdecreasedTNF-showingimprovementinaspects
of pre-diabetes and diabetes. It is therefore noteworthy that a number of TNF-
blockers (marketed as Remicade, Enbrel, Humira, and Cimzia), used in condi-
tions such as juvenile idiopathic arthritis and Crohn’s disease, are now the
subjectofanFDAsafetyreviewregardingthepossibilitythattheseagentsmaybe
causally related to development of lymphoma and other cancers in children and
young adults. Potential applications to treatment of insulin-resistant states will
undoubtedly need to be considered possibly dangerous.
Antiepileptic drugs, which are extensively used in the treatment of painful dia-
betic neuropathy, have been shown to have approximately twice the risk of
suicidal behavior or ideation (0.43%) as seen in patients receiving placebo
(0.22%). Such symptoms have been observed from 1 to 24 weeks after starting
the antiepileptic drugs, including carbamazepine (marketed as Carbatrol,
Equetro, Tegretol, and Tegretol XR), felbamate (marketed as Felbatol), gabap-
entin (marketed as Neurontin), lamotrigine (marketed as Lamictal), levetiracetam
(marketed as Keppra) oxcarbazepine (marketed as Trileptal), pregabalin (marketed
as Lyrica), tiagabine (marketed as Gabitril), topiramate (marketed as Topamax),
valproate (marketed as Depakote, Depakote ER, Depakene, Depacon), and zoni-
samide (marketed as Zonegran).
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issue of pill vs. injection; however, the
majority of the exenatide studies in the
meta-analysis had baseline A1C 8.5%,
while most of the DPP-4 inhibitor studies
had baseline 8%, potentially explaining,
in part, the greater reduction in A1C with
theformeragent.DeFronzoconcludedby
recommending that type 2 diabetic pa-
tients receive “triple agent therapy from
the beginning” with pioglitazone, met-
formin, and exenatide, speculating that it
might even be reasonable to begin phar-
macologic treatment when patients de-
velop impaired glucose tolerance or,
perhaps, even at the time of development
of insulin resistance, to prevent the pro-
gressive loss of -cells that has typically
occurred by the time of presentation of
type 2 diabetes.
Clinically based treatment
considerations
Mary Ann Banerji (New York, NY) dis-
cussed clinical beneﬁts and side effects of
glucose-lowering medications at the ADA
Postgraduate Course. Diabetes is one of
the most common noncommunicable
diseases worldwide, with prevalence pre-
dicted to increase to 370 million by the
year 2030, driven in part by the increas-
ing prevalence of obesity. Epidemiologic
evidence does not suggest a threshold
A1C for adverse macro- and microvascu-
lar outcomes (21). The ADA recommen-
dations are, then, to target “the lowest
A1C possible without unacceptable hy-
poglycemia, with action recommended
for A1C 7%.” Given these concepts, the
intensivenessofpharmacologictreatment
ofdiabetesintheU.S.hasincreased,butit
is not clear that glycemia is improving.
Rather, with conventional approaches,
A1C typically remains elevated (22). The
current recommendation is that met-
formin be given to all patients (23) and
that addition of basal insulin, a sulfonyl-
urea, or a TZD be considered, although
Banerji recommended, “just be careful
aboutglitazones.”TheAgencyforHealth-
care Research and Quality (www.ahrq.
gov), has posed the following question:
“Do oral diabetes medications for the
treatment of adults with type 2 diabetes
differintheirabilitytoaffectthefollowing
proximal clinical outcomes: A1C, blood
pressure, lipids, w[eigh]t, [and] 2 hour
postprandial glucose?” Banerji reviewed
someoftheavailableinformationthatcan
be used to address these basic points.
The UKPDS showed that use of sulfo-
nylureas, metformin, or insulin did not
maintain patients at goal (24,25). In the
ADOPT study, after 2 years, as DeFronzo
discussed, rosiglitazone was best at main-
taining glycemia. Meta-analysis of a large
number of placebo-controlled studies
showed mean A1C lowering of 1% with
pioglitazone, 1.2% with rosiglitazone,
1.1% with metformin, 1.5% with sulfo-
nylureas, 0.5% with nateglinide, and
0.8% with acarbose (26), leading to the
suggestion that the newer agents are not
as potent, although this analysis does not
control for baseline levels, with Banerji
noting that studies beginning at higher
baseline A1C levels report greater falls
(27),makingitlikelythattheseemingdif-
ferences between agents are largely expli-
cablebystudiescarriedoutfromdifferent
starting points. “Combination therapy
doeswork,”shenoted,inparticularciting
beneﬁts of administration of metformin
with sulfonylureas and with TZDs. There
is evidence that triple therapy is similarly
effective when either rosiglitazone or in-
sulin glargine is added to a metformin-
sulfonylurea combination, although with
greater beneﬁt of insulin seen at high bas-
line A1C levels (28). There is a 2–3
mmHgdropinbloodpressurewithTZDs,
a further potential beneﬁt of these agents.
The meta-analysis showed, however, that
both TZDs increased LDL cholesterol, al-
though they also increased HDL choles-
terol; pioglitazone decreased while
rosiglitazoneincreasedtriglyceridelevels.
In comparison with metformin, weight
increased both with sulfonylureas and
with TZDs, without a signiﬁcant differ-
ence between the effect of these two
classesinthemeta-analysis.Acarbosewas
weightneutral,andthishasbeenBanerji’s
clinical experience with metformin as
well. In the ADOPT study, weight de-
creased with metformin and at 5 years
was 6.9 and 2.5 kg more with rosiglita-
zone and with glyburide, respectively.
The meglitinides are also useful agents.
Continuous glucose monitoring of type 2
diabetic patients shows glycemic varia-
tion to lead to increased oxidative stress
(29), which may be related to a greater
regression of carotid intima-media thick-
ness reported in association with repa-
glinide than with glyburide (30). Similarly,
nateglinide’s particular effect on post-
prandial glycemia leads it to cause less
hypoglycemia than glyburide (31).
Banerjicharacterizedcongestiveheart
failure with TZDs as “a real problem,”
such that patients with strong risk factors
for heart failure, including having previ-
ously had heart failure, should not be
considered good candidates for these
agents (32). In contrast, stable heart fail-
ure is no longer considered a contraindi-
cation to use of metformin. If a patient
with edema is receiving drugs associated
with ﬂuid retention such as nonsteroidal
anti-inﬂammatory agents or has a local
cause such as venous insufﬁciency, the
excess ﬂuid retention caused by the TZD,
although not representing heart failure,
may still be an issue. Fracture and macu-
lar edema are additional concerns with
TZDs. Lactic acidosis in patients treated
with metformin and low cardiac output
andgastrointestinalsymptomsinpatients
treated with metformin, as well as acar-
bose and exenatide, are additional drug-
related adverse effects that may be
relevant to the choice of treatment for a
given individual. Other patient-speciﬁc
factors for deciding on a treatment ap-
proachincludetheindividual’sriskofhy-
poglycemia and of weight gain, their
degree of hyperglycemia, and whether
there is evidence of renal or hepatic dis-
ease. Given these considerations, Banerji
suggested that all the oral agents may be
appropriate, in different patients, for
“ﬁrst-line” use.
Foranindividualwithdiabetes,treat-
ment with insulin requires a complex set
of behaviors. Banerji cited a survey re-
portingthatpatientsconsidertherequire-
ment for insulin to be as disadvantageous
as having a major complication (33). Al-
thoughthisislikelytodependontheskill
ofthehealthcareproviderinencouraging
insulin use, one should certainly be cog-
nizant of quality-of-life factors when con-
sidering whether to recommend insulin.
Banerji also pointed out that decision
makingstrictlyonthebasisofA1Cfailsto
take into account the variability of its re-
lationship to glycemia, such that a person
with a mean glucose of 150 mg/dl might
have an A1C level ranging from 6.5 to
7.4%—a concept recently addressed in
some detail elsewhere (34).
The second question asked by the
Agency for Healthcare Research and
Quality is whether treatment of type 2 di-
abetesdecreasedmicro-andmacrovascu-
larcomplications.IntheDiabetesControl
and Complications Trial/Epidemiology of
Diabetes Interventions and Complica-
tions, there was decreased cardiovascular
risk after many years of follow-up (35).
Macrovascular outcome beneﬁt was not
shown with insulin and sulfonylureas in
the UKPDS, and although diabetes-
related mortality was lower with met-
formin monotherapy, it was signiﬁcantly
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with sulfonylureas in this study. Banerji
extendedDeFronzo’sideasonPROactive,
pointing out that in addition to there be-
ing no signiﬁcant beneﬁt of pioglitazone
in primary outcome, the signiﬁcant re-
duction in death, myocardial infarction
(otherthansilent),andstrokeappearedto
be accounted for by decreased A1C, tri-
glyceride, and blood pressure and in-
creasedHDLlevelsandcouldwellbesaid
tohavebeenoffsetbyincreasedheartfail-
ure and peripheral arterial disease events.
Overall, she concluded, evidence of dif-
ferences in outcome between different
oral antidiabetic agents is weak.
Considerations related to ADA
treatment guidelines
RobertRatner(Washington,DC)spokeat
the Metropolitan Diabetes Society meet-
ing on the ADA/European Association for
the Study of Diabetes guidelines, giving
his alternative approach to the treatment
of type 2 diabetes. He noted that the
guidelines recommend initiation of treat-
ment with lifestyle interventions plus
metformin upon diagnosis of diabetes,
while the strategy adopted in the UKPDS
involved a 3-month lifestyle intervention,
during which A1C fell from 9% to 7%.
Might lifestyle intervention alone, then,
be a useful strategy for some diabetic pa-
tients? The newest version of the guide-
lines suggests that TZDs may not be as
safe as other approaches to second-line
treatment because of issues with heart
failure and bone loss; Ratner asked
whether this constitutes an appropriate
rejection of the use of these agents. Fur-
thermore, he questioned the use of 7% as
the A1C target for therapeutic decision
making advocated by the guidelines,
pointing out that only a minority of dia-
betic patients achieve A1C 7%. In an
analysis of some 300,000 A1C tests per-
formed at a clinical laboratory, just 45%
of levels were 7%, and many of these
were 6%, suggesting that these tests
might have been performed for diagnosis
ratherthanpartoffollowingtreatment.In
the ADA physician-recognition program
describing the “best patients” in the “best
centers,” Ratner noted, only 25% of pa-
tients had A1C 7% in 1997, 37% in
2001, and 46% in 2003. An algorithm-
driven treatment protocol implemented
in Boston led to only half of patients
achieving A1C 7% (36). Ratner con-
cluded, “There’s got to be something
moretogettheA1Cdown.”Theproblem,
he pointed out, is the progressive loss of
glycemic control over time characteristic
of type 2 diabetes. In the UKPDS, as dis-
cussed by Banerji, at 3, 6, and 9 years,
45, 30, and 20% of treated patients, re-
spectively, maintained A1C 7%. In
ADOPT, one-third of individuals receiv-
ing glyburide, one-quarter of those re-
ceiving metformin, and one-ﬁfth of those
receiving rosiglitazone failed at 5 years
with regard to the much more readily
achieved goal of reaching fasting blood
glucose 180 mg/dl. “Is the problem
withourpatientsandourdoctors,”Ratner
asked, “or is it with our interventions?”
Ratner suggested that although all di-
abeticindividualscaninprincipleachieve
A1C 7% with insulin, large doses are
required, and the patient and physician
must accept high levels of hypoglyce-
mia—and weight gain. In the Treating to
Target in Type 2 Diabetes study of 708
individuals with sulfonylurea and met-
formin failure, randomized to aspart
70/30twicedaily,detemirdaily,oraspart
threetimesdailyandusingacarefullyfol-
lowed algorithm, 9, 18, and 4%, respec-
tively, required the addition of another
insulin dose, with ﬁnal treatment dose
0.52, 0.49, and 0.61 units   kg
1   day
1
and with A1C decreasing to 7.3, 7.6, and
7.2% from a baseline level of 8.4% (37).
Why, he asked, did not every patient
achieve an A1C level 7%? This goal was
infactattainedinthestudyinonly42,28,
and 49% of treated individuals. A conclu-
sion may be that “we do not have the sys-
tems. . .todeliveroptimumdiabetescare
to the masses” and that we need newer
and better treatment approaches. Fur-
ther, Ratner commented, “we are being
naive if we believe that . . . the only goal”
is to achieve an A1C level 7% or, ac-
cording to the more aggressive American
Association of Clinical Endocrinologists
guidelines, 6.5%. Weight-neutral, or,
better, weight loss–inducing treatment
approaches with lower risk of signiﬁcant
hypoglycemia are required to maximize
patient adherence, as well as to reduce
cardiovasculardiseaseriskandcardiovas-
cular disease outcomes. New drugs must
be safe and must also be effective, with
physicians recognizing that “diabetes is a
serious disease” with a complex risk-
beneﬁtequation.Weightgainisseenwith
TZDs, sulfonylureas, and insulin, and hy-
poglycemiaisseenwithsulfonylureasand
particularly with insulin, with 20% of
prandialinsulinpatientsintheTreatingto
Target in Type 2 Diabetes study experi-
encing it. New agents such as the DPP-4
inhibitors and incretin mimetics fulﬁll
some of these needs, although neither al-
lows the majority of patients to achieve
goal, with Ratner suggesting that “these
drugs seem to work better the earlier you
give them.” Initial sitagliptin plus met-
formin does appear to potentially be a
very effective approach, while only ap-
proximately 45% of persons taking sita-
gliptin as add on to metformin or to
pioglitazone attain A1C 7%. It will be
crucial to develop durability data, such as
the 5-year data from ADOPT and the 10-
year data from UKPDS. “We need new
therapies,” Ratner said, “because we’re
not doing well with what we’ve got.....
Even in our clinical trials,” he continued,
“[only] 45-50% are achieving target.”
An unmet need is to alter the natural
history of insulin secretory failure, recog-
nizing that at present we have no real way
of measuring -cell preservation. Even
more, we need to develop agents such as
AGEblockersandproteinkinaseCinhib-
itors, which reduce the adverse effect of
hyperglycemia. Ratner acknowledged the
need for long-term safety and efﬁcacy
data but suggested that there is a “need to
go beyond the cost of the drugs,” as phar-
maceutical treatments comprise only
11%ofhealthcarecosts.Cost,hepointed
out, is much more strongly associated
with complications than with medica-
tions (38). Furthermore, although blood
pressure treatment is highly cost-
effective, other interventions considered
reasonable, such as mammography in
older women and lipid-lowering treat-
ment,havecostsperquality-adjustedlife-
year roughly comparable with those of
glycemic control (39).
Perspectives on TZDs and
cardiovascular disease
Ratner also spoke at the ADA Postgradu-
ate Course, discussing the risk-to-beneﬁt
ratio of the TZDs, using material given at
theFoodandDrugAdministration(FDA)
hearinginJuly2007,availablefromwww.
FDA.gov/ohrms/dockets/ac/07/slides/
2007–4308s1–00-index.htm. He gave a
set of disclosures of his research support,
advisory boards, and stock ownership, as
wellashis“intellectualdisclosure”thathe
is examining the effect of rosiglitazone on
coronary atherosclerosis, as measured by
intravascular ultrasound. The TZDs, he
said, target insulin resistance, improve
glycemic control, do not cause hypogly-
cemia, improve lipids (in different ways
with different agents), and appear to ben-
eﬁt -cell function. The troglitazone ex-
perience,withtheidiosyncraticsideeffect
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multiple potential beneﬁts of this class, is
important to note “because we’ve come
fullcircle”torealizingtheTZDclasseffect
of reducing liver fat, with preliminary ev-
idence of improvement in nonalcoholic
steatohepatitis. Ratner suggested that,
similarly, we should not rush to decide
that there is cardiac toxicity associated
with any currently used TZD. The TZDs
do have side effects. Weight gain is typi-
cal, although correlating with the degree
of improvement in A1C. The greatest
weight gain is seen in patients receiving
sulfonylureas and with insulin treatment,
and this can be attenuated with caloric
restriction. TZDs are associated with
edema, particularly when used in combi-
nation with insulin, although with no
evidence of decrease in cardiac perfor-
mance. Left ventricular contractility,
stroke volume, cardiac index, systemic
vascularresistance,andbloodpressureall
improve, as documented initially with
troglitazone (40). The edema and heart
failure associated with TZD use, then, are
related to volume overload and preload
rather than to intrinsic adverse cardiac ef-
fect; this was addressed in the ADA/
American Heart Association consensus
statement on TZD use and ﬂuid retention
(32).
As discussed by DeFronzo, both the
Diabetes Prevention Program and TRI-
POD studies suggested that administra-
tion of the troglitazone led to -cell rest,
reducing progression of pre-diabetes to
diabetes by 75% during 1.5 years and by
55% over 2.5 years, respectively, with
similar reductions in development of dia-
betes by approximately 60% in the ACT
NOW and DREAM studies. The ADOPT
trial showed that in newly diagnosed type
2 diabetic patients, glycemic control was
more durable with rosiglitazone than
with metformin or glyburide. Ratner
pointed out that TZDs, then, reduce de-
velopment of diabetes and lower A1C,
while improving insulin sensitivity, low-
ering free fatty acids, improving blood
pressure, decreasing albuminuria, lower-
ingC-reactiveprotein,andincreasingadi-
ponectin. Reduction of carotid intima-
media thickness has been shown with
troglitazone (41), pioglitazone (42–44),
and rosiglitazone (45). TZDs have also
been shown to markedly reduce rates of
restenosis following coronary angioplasty
andstentprocedures(46),todecreasehe-
patic steatosis and improve steatitis (47),
and to reduce waist-to-hip ratio. Lipid ef-
fects differ somewhat between rosiglita-
zone and pioglitazone, with both
loweringfreefattyacidsbutwiththelatter
having greater effect in reducing triglyc-
erides and not changing LDL, which in-
creases with rosiglitazone, whereas HDL
cholesterol increases 2.4 and 5.2 mg/dl,
respectively, with the two agents (48). Al-
though TZDs increase heart failure rates,
following hospitalization, individuals
who have received TZDs have better clin-
ical outcome (49), further suggesting a
beneﬁt of the approach. In the PROactive
trial, there was a 10% reduction in the
primary outcome (from 23.5 to 21%)
among individuals receiving placebo vs.
pioglitazone over 36 months (12). As
event rates only began to separate around
24 months, Ratner commented, it is en-
tirely possible that a longer trial would
have shown stronger evidence of beneﬁt.
ReportsoftheBypassAngioplastyRe-
vascularization Investigation 2 Diabetes
(BARI-2D), the Action to Control CV
Risks in diabetes (ACCORD), and the
Rosiglitazone Evaluated for Cardiac Out-
comesandRegulationofGlycaemiainDi-
abetes (RECORD) trials will soon be
available, although Ratner cautioned that
power calculations suggest that patients
already receiving aspirin, converting en-
zyme inhibitors, and statins have rela-
tively low event rates, such that larger
numbers are needed than was recognized
whenthesetrialsbegan.TheDREAMtrial
suggested that cardiovascular outcomes
increased with rosiglitazone, although
only the increase in heart failure was sig-
niﬁcant. In a controversial meta-analysis
purporting to show an adverse cardiovas-
cular effect of rosiglitazone (50), myocar-
dial ischemia events were post hoc,
nonadjudicated end points; there was no
access to the actual data; and of the 42
studiesused,only11werepeerreviewed,
with 26 never published. There were
small numbers of events, and the trials
were of short duration. It has been said,
Ratner commented, that “meta-analysis is
to analysis as metaphysics is to physics”
(51), with the reported increase in risk
belied by the identical incidence of myo-
cardial ischemia events in the rosiglita-
zone and control groups: 0.6 and 0.62%,
respectively. The meta-analysis must,
then, give greater weight to some than to
otherstudies.Areanalysisofthesedataby
theFDAusingpatient-leveldatafoundno
increaseinwhatwastermed“seriousisch-
emia” and found a nonsigniﬁcant differ-
ence between the 0.73 and 0.67%
respective risks of the combination of di-
agnosed myocardial infarction, cardio-
vascular disease, and stroke, although the
combination of serious plus non-serious
ischemia risk was 2 vs. 1.5%, a signiﬁcant
increase.Theincreasedriskofmyocardial
ischemia was particularly seen when ros-
iglitazone was administered to individu-
als taking insulin or nitrates, ﬁndings
which were incorporated into revised
product labeling. Further criticism of the
original meta-analysis includes its failure
to perform a continuity correction, with
such analyses demonstrating no signiﬁ-
cant adverse effect of rosiglitazone (52).
Ratner acknowledged that “the trends
[withrosiglitazonevs.pioglitazone]arein
opposite directions” but questioned the
suggestion that the former agent has
caused more than 100,000 deaths. The
Veterans Health Administration study of
the relationship between all-cause mor-
tality and oral antidiabetic drugs showed
that with adjustment for age, diabetes du-
ration, A1C, creatinine, cardiovascular
history, lipid and blood pressure treat-
ment, and diabetes-related physician vis-
its, there was no signiﬁcant difference in
mortality among 39,721 diabetic patients
treated with sulfonylureas, metformin,
TZDs, combinations, or no drugs (53).
Analysis of a managed-care medication
dataset from WellPoint, Inc., in the FDA
presentation compared 22,050 individu-
als receiving rosiglitazone, 23,768 receiv-
ing pioglitazone, and 120,771 receiving
other agents. Those receiving TZDs were
older and had more hospitalizations and
higher rates of complications than indi-
viduals using other oral hypoglycemic
agents,butthecomparisonfailedtoreveal
differences between the two with regard
to myocardial infarction or other compli-
cations. The Data Safety Monitoring
Boards of the BARI 2D and ACCORD tri-
als, both using rosiglitazone, failed to
show an adverse cardiovascular effect of
the agent.
The risk-beneﬁt calculation for TZDs
must, then, take into account their glyce-
mic beneﬁt in monotherapy and as adju-
vants. They have added beneﬁt in
preventing diabetes development and in
maintaining glycemic control; may have
beneﬁcial -cell effects, reduce liver fat,
and reduce progression of nonalcoholic
steatohepatitis; and have pleiotropic that
may decrease cardiovascular risk. They
do increase weight and cause ﬂuid reten-
tion and, now, have been shown to
increase fractures. Furthermore, pioglita-
zone and rosiglitazone have different
characteristics. “The available evidence,”
Ratner concluded, “is insufﬁcient to de-
Bloomgarden
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duce, or have a neutral effect on ischemic
CVD or death.”
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